Update on the medical treatment of Graves＊ ophthalmopathy

作者：Gregory J Griepentrog; James A Garrity

来源：International Journal of General Medicine, 2009.

DOI：http://dx.doi.org/10.2147/IJGM.S6856

• Graves&rsquo
• ophthalmopathy
• thyroid eye disease
• thyroid-associated ophthalmopathy

ate on the medical treatment of Graves＊ ophthalmopathy Review (5535) Total Article Views Authors: Gregory J Griepentrog, James A Garrity Published Date December 2009 Volume 2009:2 Pages 263 - 269 DOI: http://dx.doi.org/10.2147/IJGM.S6856 Gregory J Griepentrog, James A Garrity Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA Purpose: To review recent advances in the understanding of Graves＊ ophthalmopathy (GO) pathogenesis as well as discuss current and future medical management strategies. Design: Interpretive essay. Methods: Literature review and interpretation. Results: Medical treatment of GO has slowly evolved during the past few decades and has been hampered by a poor understanding of the disease at a cellular and molecular level. Current treatment recommendations and guidelines therefore focus on nonspecific immuno-suppression. Newer classes of treatment agents hold promise to more selectively target underlying cellular and molecular alterations in GO. Conclusion: Cooperation between individual patients, physicians and between differing medical centers, together with a refined understanding of the pathogenesis of GO, will lead to newer more-effective treatments for the disease and improve patient quality of life.